Peripheral adenosine infusion versus central access infusion during measurement of FFR

Original title: FFR in the Transradial Era: Will Hand Vein Adenosine Infusion Suffice?A Comparative Study of the Extent, Rapidity, and Stability of Hyperemia From Hand and Femoral Venous Routes of Adenosine Administration. Reference: Peter Scott et al. J Am Coll Cardiol Intv. 2015, online before print.

 

The aim of this study was to compare the administration of adenosine by a path in the back of the hand versus the same drug administration using a central venous access and observe differences to reach peak hyperemia during measurement of fractional flow reserve (FFR). Adenosine is commonly used to achieve maximum hyperemia during the measurement of FFR and the gold standard is administered by a central venous access. With the proliferation of radial access is desirable to have an alternative route around, however, it is unclear whether it is possible to achieve maximum hyperemia using a peripheral access.

Patients scheduled for FFR measurement were selected and administered adenosine sequentially through a 20G cannula into the back of the hand and after a washout of the drug, adenosine was re-administered through an inserter 5 or 6 Fr in the femoral vein. Adenosine was given at 140 ug / kg / min for each access. The interpretation of the data was blind regarding the administration via. Measurements were performed in 84 vessels of 61 patients with a mean value of FFR of 0.85 (0.986 correlation between both accesses). Hyperemia peak time was different, requiring an average of 22 seconds more for peripheral access (63 seconds versus 43 seconds; p <0.0001).

Conclusion

Adenosine infusion during FFR measurement by peripheral access is similar to the administration thereof by central access. This is important from a practical point of view for performing radial access procedures.

Editorial comment

In the FAME study, according to protocol, 140 ug / kg / min of adenosine by femoral venous access were administered and although in daily practice this same dose was often administered peripherally, there was so far, no evidence that it was equivalent. This is an interesting technical detail which increases the comfort of patients receiving radial access in the procedure.

SOLACI

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...